ClinicalTrials.gg
Active, not recruitingNCT04165317CRESTUpdated Oct 15, 2026Results posted

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

A Phase 3 interventional study of PF-06801591 and Bacillus Calmette-Guerin in Non-muscle Invasive Bladder Cancer, sponsored by Pfizer. Active, not recruiting at 196 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Oct 15, 20267 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,068
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms — 6 open to participants now, 12 under way, 5 of them phase 3. BCG Vaccine · Non-Muscle Invasive Bladder Neoplasms.

Enrollment
Largest of 17
1,068 · median 160
Started
2019
with 2 others
Phase 3
6 of 17
2 open now
Primary completion
2024-12
later than 1 of 11 live
Registered
5th of 17
by date

Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, this one has the largest enrollment, is one of 3 that started in 2019, is one of 6 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 5th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

6 of the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B).

In Part A (enrollment closed), each participant was assigned to one of three study treatment groups.

  • One group is given sasanlimab and BCG at the study clinic.
  • The second group is given sasanlimab and BCG at the study clinic. This group will receive BCG for the first six weeks only.
  • The third group is given BCG only and will not receive sasanlimab.

In Part B of the study, each new participant will be assigned to a study treatment group based on the type of their bladder tumor.

- Both groups will be given sasanlimab at the study clinic.

On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B. The decision to discontinue enrollment to Part B was not made for safety reasons.

Read the detailed description

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment

Phase 3 Design with two Cohorts. Cohort A consists of 3 study Arms (A, B and C) of BCG naive participants. Arms A and B consist of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. Cohort B consists of B1 and B2, which test PF-06801591 and include participants who have BCG unresponsive CIS (B1) or BCG unresponsive papillary only disease (B2).

The study is designed to demonstrate that PF-06801591 plus Bacillus Calmette Guerin (BCG) (induction and maintenance periods) is superior to BCG alone (induction and maintenance periods) in prolonging event free survival (EFS) in participants with high-risk naïve non-muscle invasive bladder cancer (NMIBC) and to demonstrate that PF-06801591 plus BCG (induction period only) is superior to BCG alone (induction and maintenance periods) in prolonging EFS in participants with high-risk NMIBC. The study is also designed to estimate the CR rate of PF-06801591 alone in participants with BCG unresponsive CIS and to evaluate the EFS of PF-06801591 alone in participants with BCG unresponsive NMIBC.

On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B, which enrolled participants with BCG unresponsive NMIBC. The decision to discontinue enrollment to Part B was not made for safety reasons.

03

Conditions studied

  • Non-muscle Invasive Bladder Cancer

Keywords

  • CREST
  • Sasanlimab
  • PF-06801591
  • Bacillus Calmette Guerin
  • BCG
  • Bladder cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmed diagnosis of high risk non-muscle invasive transitional cell carcinoma (TCC) of the urothelium of the urinary bladder (tumors of mixed transitional/non-transitional cell histology are allowed, but TCC must be the predominant histology)
  • Complete resection of all Ta/T1 papillary disease (including participants with concurrent CIS), with most recent positive TURBT occurring within 12 weeks prior to randomization or study intervention. A second TURBT must have been performed if indicated according to the current locally applicable guidelines, ie, American Urological Association, European Association of Urology
  • (Cohorts B1 and B2 only): Histological confirmed diagnosis of BCG-unresponsive high-risk, non-muscle invasive TCC of the urothelium within 12 months (CIS only) or 6 months (recurrent Ta/T1 disease) of completion of adequate BCG therapy.
  • Have refused or are ineligible for radical cystectomy

Exclusion criteria

Exclusion Criteria:

  • Evidence of muscle-invasive, locally advanced or urothelial cancer or concurrent extravesical, non-muscle invasive TCC of the urothelium
  • (Cohort A only): Intravesical BCG therapy within 2 years prior to randomization. Prior intravesical chemotherapy for NMIBC is allowed.

(Cohorts B1 and B2 only): Any systemic or intravesical chemotherapy or immunotherapy from the time of most recent positive TURBT to initiation of study intervention.

  • Prior immunotherapy with anti , anti PD-L1, anti PD-L2, or anti cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody
  • Prior treatment with immunostimulatory agents including interleukin (IL)-2, IL-15, interferon (INF)
  • Prior radiation therapy to the bladder
  • (Cohorts B1 and B2 only): Prior participation in Cohort A of this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,068 participants (actual)

Study arms

  • Experimental
    PF-06801591 + BCG induction and maintenance

    PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).

    Drug: PF-06801591 · Drug: Bacillus Calmette-Guerin

  • Experimental
    PF-06801591 + BCG induction only

    PF-06801591 in combination with Bacillus Calmette Guerin (induction only).

    Drug: PF-06801591 · Drug: Bacillus Calmette-Guerin

  • Active comparator
    BCG induction and maintenance

    Bacillus Calmette Guerin (induction and maintenance).

    Drug: Bacillus Calmette-Guerin

  • Experimental
    BCG Unresponsive CIS

    PF-06801591

    Drug: PF-06801591

  • Experimental
    BCG Unresponsive NMIBC

    PF-06801591

    Drug: PF-06801591

Interventions

  • A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.

    Also known as: Sasanlimab

  • Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer

    Also known as: BCG

06

What researchers measure

Primary outcomes

  1. Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C

    EFS: time from randomization till recurrence of high-grade disease, progression of disease, persistence of carcinoma in situ (CIS), death due to any cause, whichever occurred first. Recurrence of high-grade disease: re-appearance of high-grade disease after randomization/study intervention initiation, re-appearance of high-grade disease after complete response (CR) for CIS participants or re-appearance of high-grade disease before CR for CIS participants and concurrent papillary disease at baseline. Progression of disease defined as any of following: Lamina propria invasion, muscle invasive disease, lymph node positive disease, metastatic disease, high-grade stage of bladder cancer (non-invasive papillary carcinoma \[Ta\] or invasion into the lamina propria without invasion into the muscularis propria \[T1\]) in participants with CIS only at baseline before achieving CR. Persistence of CIS: persistent CIS after induction, re-induction. EFS estimated using Kaplan-Meier analysis.

    Time frame: From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)

Secondary outcomes

  1. Cohort A: EFS as Assessed by the Investigator: Arm B Versus Arm C

    EFS: time from randomization till recurrence of high-grade disease, progression of disease, CIS, death due to any cause, whichever occurred first. Recurrence of high-grade disease: re-appearance of high-grade disease after randomization/study intervention initiation, re-appearance of high-grade disease after CR for CIS participants or re-appearance of high-grade disease before CR for CIS participants and concurrent papillary disease at baseline. Progression of disease defined as any of following: Lamina propria invasion, muscle invasive disease, lymph node positive disease, metastatic disease, high-grade stage of bladder cancer (non-invasive papillary carcinoma \[Ta\] or invasion into the lamina propria without invasion into the muscularis propria \[T1\]) in participants with CIS only at baseline before achieving CR. Persistence of CIS: persistent CIS after induction, re-induction. EFS estimated using Kaplan-Meier analysis.

    Time frame: From randomization (Day 1) to the first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)

  2. Cohort A: Overall Survival (OS) for Participants: Arm A Versus Arm C

    Overall survival was defined as the time in months from the date of randomization to the date of death due to any cause. Participants last known to be alive will be censored at the date of last contact

    Time frame: From randomization (Day 1) until date of death due to any cause or censoring date

  3. Cohort A: OS of Participants: Arm B Versus Arm C

    Overall survival was defined as the time in months from the date of randomization to the date of death due to any cause. Participants last known to be alive will be censored at the date of last contact.

    Time frame: From randomization (Day 1) until date of death due to any cause or censoring date

  4. Cohort A: Percentage of Participants With Complete Response (CR)as Assessed by Investigator: Participants With CIS at Baseline in Full Analysis Set

    CR was defined as histologic disappearance of malignancy on bladder biopsy with negative cytology and cystoscopy or negative cytology and positive cystoscopy with biopsy-proven low-grade stage of bladder cancer defined as a non-invasive papillary carcinoma (Ta) lesion or non-malignant tissue for participants with CIS at randomization. 95% CI was based on Clopper-Pearson method.

    Time frame: From randomization (Day 1) to the first documented CR (maximum follow up duration was up to 257.1 weeks)

  5. Cohort A: Duration of CR as Assessed by the Investigator: Participants With CIS at Baseline in Full Analysis Set

    Duration of CR was defined as the time from the first documentation of CR to the date of an EFS event for participants with CR. EFS was defined as the time in months from randomization until recurrence of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first. CR was defined as histologic disappearance of malignancy on bladder biopsy with negative cytology and cystoscopy or negative cytology and positive cystoscopy with biopsy-proven low-grade stage of bladder cancer defined as a non-invasive papillary carcinoma (Ta) lesion or non-malignant tissue for participants with CIS at randomization. Kaplan-Meier method was used. 95% CI was estimated based on Brookmeyer and Crowley method.

    Time frame: From date of first documentation of CR to date of an EFS event (maximum follow up duration was up to 257.1 weeks)

  6. Cohort A: Time to Recurrence of Low-Grade Disease Assessed by the Investigator

    Time to recurrence of low-grade disease was defined as the time from randomization to the date of first documentation of recurrence of low-grade disease. Recurrence of low-grade disease was defined as re-appearance of low-grade disease (low-grade Ta) after randomization based on positive biopsy, cystoscopy or cytology result. Kaplan-Meier method was used. 95% CI was estimated based on Brookmeyer and Crowley method.

    Time frame: From randomization (Day 1) to the date of positive biopsy, cystoscopy or cytology results (maximum follow up duration was up to 257.1 weeks)

  7. Cohort A: Time to Cystectomy

    Time to cystectomy was defined as time from randomization to cystectomy. Participants without a cystectomy will be censored at death date or last date known to be alive.

    Time frame: From randomization (Day 1) to date of cystectomy or censoring date

  8. Cohort A: Disease Specific Survival (DSS) as Assessed by the Investigator

    DSS was defined as the time from randomization to death resulting from bladder cancer, as assessed by the investigator. Participants last known to be alive will be censored at the date of last contact.

    Time frame: From randomization (Day 1) to the first documentation of death from bladder cancer

  9. Cohort A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

  10. Cohort A: Number of Participants With Serious TEAEs

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death or was life threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or other events.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

  11. Cohort A: Number of Participants With Treatment Related TEAEs and Treatment Related SAEs

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. A SAE was any untoward medical occurrence at any dose that: resulted in death or was life threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity resulted in congenital anomaly/birth defect or other events. Relatedness was based on the investigator's judgement.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

  12. Cohort A: Number of Participant With Grade 3 or 4 and Grade 5 TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. NCI-CTCAE version 5.0, severity was graded as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe and Grade 4 Life threatening and Grade 5: Death.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

  13. Cohort A: Number of Participant With Laboratory Abnormalities as Based on Severity (as Graded by NCI CTCAE v5.0)

    Laboratory parameters: hematocrit, hemoglobin, platelets, white blood cells, absolute neutrophil count, lymphocytes, monocytes, eosinophils, basophils, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium and bilirubin, blood urea nitrogen, urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus/phosphate, lipase, amylase, thyroid function test + reflex free thyroxine, free triiodothyronine, adrenocorticotropic hormone, international normalized ratio, partial thromboplastin time (PTT)/activated PTT, hepatitis B surface antigen, hepatitis C virus antibody. Severity grades per NCI-CTCAE v5.0: 1: Mild, 2: Moderate, 3: Severe, 4: Life threatening,5: Death.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

  14. Cohort A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Non-Muscle Invasive Bladder Cancer (QLQ-C) 30 Total Score

    The EORTC QLQ-C30 was a 30 self-administered questionnaire, which comprised of 5 functional domain subscales (physical functioning subscale, a role functioning subscale, an emotional functioning subscale, a cognitive functioning subscale and a social functioning subscale), 3 symptom scale (fatigue, pain, nausea and vomiting), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. All the scales and single-item measures range in score from 0 (poor functioning/no symptoms) to 100 (excellent functioning/greater degree of symptoms). Higher scores on functional domains indicated higher levels of functioning and higher scores on symptom scale/single items indicated greater presence of symptoms.

    Time frame: Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death

  15. Cohort A: Change From Baseline in EORTC QLQ- Non-Muscle Invasive Bladder Cancer (NMIBC24) Total Score

    The EORTC QLQ NMIBC24 is a PRO developed and tested by the EORTC group specifically for participants with non-muscle invasive bladder cancer. The NMIBC24 has 24 items which can be grouped into 6 subscales: urinary symptoms (7 items), malaise (2 items), future worries (4 items), bloating/flatulence (2 items), sexual functioning (2 items), and male sexual issues (2 items). The NMIBC24 also assesses intravesical treatment, female sexual issues, sexual intimacy, risk of contaminating a partner, and sexual enjoyment (1 item each). All of the subscales and single-item measures range in score from 0 (poor functioning/no symptoms) to 100 (excellent functioning/greater degree of symptoms). Higher scores indicate greater impairment, except for sexual function and sexual enjoyment items, where higher scores indicate better function.

    Time frame: Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death

  16. Cohort A: Change From Baseline in Patient Treatment Administration Burden (PTAB) Questionnaire Total Score

    The PTAB questionnaire was a 2-item PRO designed to assess, from the participant perspective, any pain associated with the treatment administration and the burden of the amount of time required to complete the treatment administration procedures (1 item each). The items were scored on a range of 0 to 4, where 0=no pain/ not at all burdensome and 4= extremely severe pain/ extremely burdensome.

    Time frame: Baseline up to 7 days after last dose of study treatment

  17. Cohort A: Concentration at Trough (Ctrough) of PF-06801591 for Arms A and B Only

    Concentration at Trough is defined as Predose/trough concentration Observed directly from data.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 4, 6, 8, 10 and 13 (1 cycle=4 weeks)

  18. Cohort A: Number of Participants With Positive (Anti-Drug Antibody) ADA or (Neutralizing Antibody) NAb: Arms A and B Only

    A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-fold dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

    Time frame: From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks and 104.4 weeks of treatment exposure for Arm A and Arm B, respectively)

  19. Cohort A: Number of Participants According to Tumor Sample Biomarker Status Based on Baseline Programmed Cell Death Ligand 1 (PD-L1) Expression

    PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and immune cells in regions of interest that were defined by tumor cell morphology. PDL-1 status was high if \>=25% tumor cell or (immune cells present in the tumor area \> 1% and PD-L1 positive immune cells+ \>=25%) or (immune cells present in the tumor area = 1% and PD-L1 positive immune cells = 100%), and low if \< 25% tumor cell and \[(immune cells present in the tumor area \> 1% and immune cells \<25%) or (immune cells present in the tumor area = 1% and PD-L1 positive immune cells\< 100%) or immune cells present = 0\].

    Time frame: From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks, 104.4 weeks and 110 weeks of treatment exposure for Arm A, Arm B and Arm C, respectively)

07

Results

Posted Jan 22, 2026
Limitations and caveats
Enrollment in Cohort B was closed based on sponsors decision; hence, the study objectives for Cohorts B1 and B2 were no longer required as pre-specified in the protocol; outcome measures for Cohorts B based on the data collected will be summarized and reported at the time of final analysis.

Participant flow

This study was conducted in two cohorts: Cohort A (Bacillus Calmette Guerin \[BCG\] naïve participants with non-muscle invasive bladder cancer \[NMIBC\]) and Cohort B (BCG unresponsive participants with NMIBC).

Treatment Phase
Participant flow — Treatment Phase
MilestoneCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mg
Started35235235158
Treated35034834958
Completed12116020314
Not completed23119214844
Withdrew: Adverse event131893702
Withdrew: Death88600
Withdrew: Lack of efficacy32505432
Withdrew: Lost to follow-up30200
Withdrew: Withdrawal by subject41262910
Withdrew: Global deterioration of health status02000
Withdrew: Other14131800
Withdrew: Randomized, not treated24200
Follow up Phase
Participant flow — Follow up Phase
MilestoneCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mg
Started31933033457
Completed00000
Not completed31933033457
Withdrew: Death23202300
Withdrew: Lost to follow-up46100
Withdrew: Withdrawal by subject12272100
Withdrew: Ongoing28027728900
Withdrew: Other00057

Outcome measures

PrimaryCohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C

EFS: time from randomization till recurrence of high-grade disease, progression of disease, persistence of carcinoma in situ (CIS), death due to any cause, whichever occurred first. Recurrence of high-grade disease: re-appearance of high-grade disease after randomization/study intervention initiation, re-appearance of high-grade disease after complete response (CR) for CIS participants or re-appearance of high-grade disease before CR for CIS participants and concurrent papillary disease at baseline. Progression of disease defined as any of following: Lamina propria invasion, muscle invasive disease, lymph node positive disease, metastatic disease, high-grade stage of bladder cancer (non-invasive papillary carcinoma \[Ta\] or invasion into the lamina propria without invasion into the muscularis propria \[T1\]) in participants with CIS only at baseline before achieving CR. Persistence of CIS: persistent CIS after induction, re-induction. EFS estimated using Kaplan-Meier analysis.

Time frame:
From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
Reported as:
Median · Months
Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C
MonthsCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm C: BCG (IND+MNT)
Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm CNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Cohort A, Arm A: PF-06801591+BCG (IND+MNT) vs Cohort A, Arm C: BCG (IND+MNT) · Log Rank · p = 0.0095 · Hazard ratio (hr): 0.68 · 95% CI 0.489 to 0.941Hazard ratio was based on Cox proportional hazards model.
SecondaryCohort A: EFS as Assessed by the Investigator: Arm B Versus Arm C

EFS: time from randomization till recurrence of high-grade disease, progression of disease, CIS, death due to any cause, whichever occurred first. Recurrence of high-grade disease: re-appearance of high-grade disease after randomization/study intervention initiation, re-appearance of high-grade disease after CR for CIS participants or re-appearance of high-grade disease before CR for CIS participants and concurrent papillary disease at baseline. Progression of disease defined as any of following: Lamina propria invasion, muscle invasive disease, lymph node positive disease, metastatic disease, high-grade stage of bladder cancer (non-invasive papillary carcinoma \[Ta\] or invasion into the lamina propria without invasion into the muscularis propria \[T1\]) in participants with CIS only at baseline before achieving CR. Persistence of CIS: persistent CIS after induction, re-induction. EFS estimated using Kaplan-Meier analysis.

Time frame:
From randomization (Day 1) to the first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
Reported as:
Median · Months
Cohort A: EFS as Assessed by the Investigator: Arm B Versus Arm C
MonthsCohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)
Cohort A: EFS as Assessed by the Investigator: Arm B Versus Arm C50.1 (47.1 to NA)NA (NA to NA)
Statistical analysis
  • Cohort A, Arm B: PF-06801591+BCG (IND) vs Cohort A, Arm C: BCG (IND+MNT) · Log Rank · p = 0.8439 · Hazard ratio (hr): 1.16 · 95% CI 0.870 to 1.552Hazard ratio was based on Cox proportional hazards model.
SecondaryCohort A: Overall Survival (OS) for Participants: Arm A Versus Arm C

Overall survival was defined as the time in months from the date of randomization to the date of death due to any cause. Participants last known to be alive will be censored at the date of last contact

Time frame:
From randomization (Day 1) until date of death due to any cause or censoring date

Results for this outcome have not been posted.

SecondaryCohort A: OS of Participants: Arm B Versus Arm C

Overall survival was defined as the time in months from the date of randomization to the date of death due to any cause. Participants last known to be alive will be censored at the date of last contact.

Time frame:
From randomization (Day 1) until date of death due to any cause or censoring date

Results for this outcome have not been posted.

SecondaryCohort A: Percentage of Participants With Complete Response (CR)as Assessed by Investigator: Participants With CIS at Baseline in Full Analysis Set

CR was defined as histologic disappearance of malignancy on bladder biopsy with negative cytology and cystoscopy or negative cytology and positive cystoscopy with biopsy-proven low-grade stage of bladder cancer defined as a non-invasive papillary carcinoma (Ta) lesion or non-malignant tissue for participants with CIS at randomization. 95% CI was based on Clopper-Pearson method.

Time frame:
From randomization (Day 1) to the first documented CR (maximum follow up duration was up to 257.1 weeks)
Reported as:
Number · Percentage of participants
Cohort A: Percentage of Participants With Complete Response (CR)as Assessed by Investigator: Participants With CIS at Baseline in Full Analysis Set
Percentage of participantsCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)
Cohort A: Percentage of Participants With Complete Response (CR)as Assessed by Investigator: Participants With CIS at Baseline in Full Analysis Set89.8 (81.5 to 95.2)88.2 (79.8 to 93.9)85.2 (76.1 to 91.9)
SecondaryCohort A: Duration of CR as Assessed by the Investigator: Participants With CIS at Baseline in Full Analysis Set

Duration of CR was defined as the time from the first documentation of CR to the date of an EFS event for participants with CR. EFS was defined as the time in months from randomization until recurrence of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first. CR was defined as histologic disappearance of malignancy on bladder biopsy with negative cytology and cystoscopy or negative cytology and positive cystoscopy with biopsy-proven low-grade stage of bladder cancer defined as a non-invasive papillary carcinoma (Ta) lesion or non-malignant tissue for participants with CIS at randomization. Kaplan-Meier method was used. 95% CI was estimated based on Brookmeyer and Crowley method.

Time frame:
From date of first documentation of CR to date of an EFS event (maximum follow up duration was up to 257.1 weeks)
Reported as:
Median · Months
Cohort A: Duration of CR as Assessed by the Investigator: Participants With CIS at Baseline in Full Analysis Set
MonthsCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)
Cohort A: Duration of CR as Assessed by the Investigator: Participants With CIS at Baseline in Full Analysis SetNA (NA to NA)44.6 (44.6 to NA)NA (39.3 to NA)
SecondaryCohort A: Time to Recurrence of Low-Grade Disease Assessed by the Investigator

Time to recurrence of low-grade disease was defined as the time from randomization to the date of first documentation of recurrence of low-grade disease. Recurrence of low-grade disease was defined as re-appearance of low-grade disease (low-grade Ta) after randomization based on positive biopsy, cystoscopy or cytology result. Kaplan-Meier method was used. 95% CI was estimated based on Brookmeyer and Crowley method.

Time frame:
From randomization (Day 1) to the date of positive biopsy, cystoscopy or cytology results (maximum follow up duration was up to 257.1 weeks)
Reported as:
Median · Months
Cohort A: Time to Recurrence of Low-Grade Disease Assessed by the Investigator
MonthsCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)
Cohort A: Time to Recurrence of Low-Grade Disease Assessed by the Investigator48.8 (NA to NA)NA (47.9 to NA)NA (NA to NA)
SecondaryCohort A: Time to Cystectomy

Time to cystectomy was defined as time from randomization to cystectomy. Participants without a cystectomy will be censored at death date or last date known to be alive.

Time frame:
From randomization (Day 1) to date of cystectomy or censoring date

Results for this outcome have not been posted.

SecondaryCohort A: Disease Specific Survival (DSS) as Assessed by the Investigator

DSS was defined as the time from randomization to death resulting from bladder cancer, as assessed by the investigator. Participants last known to be alive will be censored at the date of last contact.

Time frame:
From randomization (Day 1) to the first documentation of death from bladder cancer

Results for this outcome have not been posted.

SecondaryCohort A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

Results for this outcome have not been posted.

SecondaryCohort A: Number of Participants With Serious TEAEs

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death or was life threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or other events.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

Results for this outcome have not been posted.

SecondaryCohort A: Number of Participants With Treatment Related TEAEs and Treatment Related SAEs

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. A SAE was any untoward medical occurrence at any dose that: resulted in death or was life threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity resulted in congenital anomaly/birth defect or other events. Relatedness was based on the investigator's judgement.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

Results for this outcome have not been posted.

SecondaryCohort A: Number of Participant With Grade 3 or 4 and Grade 5 TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as the time from the first dose of study treatment up to 30 days after last dose of study treatment or 1 day before start day of new anti-cancer therapy. NCI-CTCAE version 5.0, severity was graded as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe and Grade 4 Life threatening and Grade 5: Death.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

Results for this outcome have not been posted.

SecondaryCohort A: Number of Participant With Laboratory Abnormalities as Based on Severity (as Graded by NCI CTCAE v5.0)

Laboratory parameters: hematocrit, hemoglobin, platelets, white blood cells, absolute neutrophil count, lymphocytes, monocytes, eosinophils, basophils, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium and bilirubin, blood urea nitrogen, urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus/phosphate, lipase, amylase, thyroid function test + reflex free thyroxine, free triiodothyronine, adrenocorticotropic hormone, international normalized ratio, partial thromboplastin time (PTT)/activated PTT, hepatitis B surface antigen, hepatitis C virus antibody. Severity grades per NCI-CTCAE v5.0: 1: Mild, 2: Moderate, 3: Severe, 4: Life threatening,5: Death.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy

Results for this outcome have not been posted.

SecondaryCohort A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Non-Muscle Invasive Bladder Cancer (QLQ-C) 30 Total Score

The EORTC QLQ-C30 was a 30 self-administered questionnaire, which comprised of 5 functional domain subscales (physical functioning subscale, a role functioning subscale, an emotional functioning subscale, a cognitive functioning subscale and a social functioning subscale), 3 symptom scale (fatigue, pain, nausea and vomiting), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/QoL scale. All the scales and single-item measures range in score from 0 (poor functioning/no symptoms) to 100 (excellent functioning/greater degree of symptoms). Higher scores on functional domains indicated higher levels of functioning and higher scores on symptom scale/single items indicated greater presence of symptoms.

Time frame:
Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death

Results for this outcome have not been posted.

SecondaryCohort A: Change From Baseline in EORTC QLQ- Non-Muscle Invasive Bladder Cancer (NMIBC24) Total Score

The EORTC QLQ NMIBC24 is a PRO developed and tested by the EORTC group specifically for participants with non-muscle invasive bladder cancer. The NMIBC24 has 24 items which can be grouped into 6 subscales: urinary symptoms (7 items), malaise (2 items), future worries (4 items), bloating/flatulence (2 items), sexual functioning (2 items), and male sexual issues (2 items). The NMIBC24 also assesses intravesical treatment, female sexual issues, sexual intimacy, risk of contaminating a partner, and sexual enjoyment (1 item each). All of the subscales and single-item measures range in score from 0 (poor functioning/no symptoms) to 100 (excellent functioning/greater degree of symptoms). Higher scores indicate greater impairment, except for sexual function and sexual enjoyment items, where higher scores indicate better function.

Time frame:
Baseline up to recurrence of high-grade disease or disease progression, consent withdrawal, lost to follow-up, or death

Results for this outcome have not been posted.

SecondaryCohort A: Change From Baseline in Patient Treatment Administration Burden (PTAB) Questionnaire Total Score

The PTAB questionnaire was a 2-item PRO designed to assess, from the participant perspective, any pain associated with the treatment administration and the burden of the amount of time required to complete the treatment administration procedures (1 item each). The items were scored on a range of 0 to 4, where 0=no pain/ not at all burdensome and 4= extremely severe pain/ extremely burdensome.

Time frame:
Baseline up to 7 days after last dose of study treatment

Results for this outcome have not been posted.

SecondaryCohort A: Concentration at Trough (Ctrough) of PF-06801591 for Arms A and B Only

Concentration at Trough is defined as Predose/trough concentration Observed directly from data.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 4, 6, 8, 10 and 13 (1 cycle=4 weeks)
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Cohort A: Concentration at Trough (Ctrough) of PF-06801591 for Arms A and B Only
Nanogram per milliliter (ng/mL)Cohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)
Cycle 1 (Day 1)NA (NA to NA)NA (NA to NA)
Cycle 2 (Day1)17530.0 (16848.8 to 18238.8)17398.8 (16569.0 to 18270.0)
Cycle 4 (Day1)30587.9 (29256.1 to 31980.4)30507.1 (29043.6 to 32044.3)
Cycle 6 (Day 1)32945.2 (31352.8 to 34618.5)34614.0 (32634.8 to 36713.2)
Cycle 8 (Day 1)35701.1 (34030.3 to 37454.0)36414.1 (33579.4 to 39488.1)
Cycle 10 (Day 1)38616.9 (36395.7 to 40973.6)38965.4 (36374.5 to 41740.9)
Cycle 13 (Day 1)41969.4 (39420.4 to 44683.3)41737.1 (39045.7 to 44614.1)
SecondaryCohort A: Number of Participants With Positive (Anti-Drug Antibody) ADA or (Neutralizing Antibody) NAb: Arms A and B Only

A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-fold dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

Time frame:
From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks and 104.4 weeks of treatment exposure for Arm A and Arm B, respectively)
Reported as:
Count of participants · Participants
Cohort A: Number of Participants With Positive (Anti-Drug Antibody) ADA or (Neutralizing Antibody) NAb: Arms A and B Only
ParticipantsCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)
ADA1919
NAb01
SecondaryCohort A: Number of Participants According to Tumor Sample Biomarker Status Based on Baseline Programmed Cell Death Ligand 1 (PD-L1) Expression

PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and immune cells in regions of interest that were defined by tumor cell morphology. PDL-1 status was high if \>=25% tumor cell or (immune cells present in the tumor area \> 1% and PD-L1 positive immune cells+ \>=25%) or (immune cells present in the tumor area = 1% and PD-L1 positive immune cells = 100%), and low if \< 25% tumor cell and \[(immune cells present in the tumor area \> 1% and immune cells \<25%) or (immune cells present in the tumor area = 1% and PD-L1 positive immune cells\< 100%) or immune cells present = 0\].

Time frame:
From start of study treatment (Day 1) until 7 days after last dose of study treatment (maximum up to 125.1 weeks, 104.4 weeks and 110 weeks of treatment exposure for Arm A, Arm B and Arm C, respectively)
Reported as:
Count of participants · Participants
Cohort A: Number of Participants According to Tumor Sample Biomarker Status Based on Baseline Programmed Cell Death Ligand 1 (PD-L1) Expression
ParticipantsCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)
High776873
Low252256253
Unknown111311

Adverse events

Collected over From first dose of study treatment (Day 1) up to 30 days after last dose of study treatment or 1 day before anti-cancer therapy (maximum follow up duration was up to 257.1 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A, Arm A: PF-06801591+BCG (IND+MNT)32/352 (9.1%)120/350 (34.3%)321/350 (91.7%)
Cohort A, Arm B: PF-06801591+BCG (IND)30/352 (8.5%)99/348 (28.4%)299/348 (85.9%)
Cohort A, Arm C: BCG (IND+MNT)29/351 (8.3%)49/349 (14%)287/349 (82.2%)
Cohort B1: PF-06801591 300 mg0/5 (0%)2/5 (40%)5/5 (100%)
Cohort B2: PF-06801591 600 mg0/8 (0%)2/8 (25%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 227
Most frequent serious events
EventCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mg
HypophysitisEndocrine disorders1/3501/3480/3491/50/8
HydronephrosisRenal and urinary disorders0/3500/3480/3491/50/8
Bundle branch block leftCardiac disorders0/3500/3480/3490/51/8
Diabetic ketoacidosisMetabolism and nutrition disorders2/3501/3480/3490/51/8
HyponatraemiaMetabolism and nutrition disorders0/3502/3481/3490/51/8
HypothyroidismEndocrine disorders0/3500/3480/3490/51/8
PneumoniaInfections and infestations9/3503/3484/3490/50/8
COVID-19Infections and infestations6/3505/3484/3490/50/8
Urinary tract infectionInfections and infestations5/3501/3481/3490/50/8
Acute kidney injuryRenal and urinary disorders3/3504/3480/3490/50/8
Most frequent other events
Showing 10 of 80
Most frequent other events
EventCohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mg
Alanine aminotransferase increasedInvestigations56/35038/34830/3492/50/8
DysuriaRenal and urinary disorders115/35072/348126/3492/50/8
Dry mouthGastrointestinal disorders0/3500/3480/3492/50/8
PruritusSkin and subcutaneous tissue disorders48/35043/3488/3491/53/8
HaematuriaRenal and urinary disorders97/35051/34890/3490/51/8
Urinary tract infectionInfections and infestations90/35054/34882/3490/52/8
FatigueGeneral disorders52/35042/34821/3491/52/8
RashSkin and subcutaneous tissue disorders0/3500/3480/3490/52/8
PollakiuriaRenal and urinary disorders83/35039/34874/3490/51/8
Lipase increasedInvestigations76/35056/34828/3490/50/8

Baseline characteristics

Full Analysis Set (FAS) Cohort A included all participants who were randomized in Cohort A. For Cohort B1 and B2, Safety Analysis Set (SAS) was used which included all participants who received at least 1 dose of study drug.

Age, Customized
Age, Customized(Participants)Cohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mgTotal
<65 years14214113323421
65 to <75 years13514114212421
75 to <85 years71626623204
>=85 years48100022
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mgTotal
Female72536700192
Male28029928458876
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mgTotal
American Indian or Alaska Native000000
Asian11513312612377
Native Hawaiian or Other Pacific Islander000000
Black or African American3250010
White22521121036655
More than one race000000
Unknown or Not Reported96101026
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A, Arm A: PF-06801591+BCG (IND+MNT)Cohort A, Arm B: PF-06801591+BCG (IND)Cohort A, Arm C: BCG (IND+MNT)Cohort B1: PF-06801591 300 mgCohort B2: PF-06801591 600 mgTotal
Ethnicity — Hispanic or Latino or of Spanish origin2225241072
Ethnicity — Not Hispanic or Latino or of Spanish origin31531431038950
Ethnicity — Not Reported1513171046
08

Study locations

196 sites

Showing the first 100 of 196 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Shore ND, Powles TB, Bedke J, Galsky MD, Redorta JP, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary. Future Oncol. 2026 Jun;22(13):1487-1499. doi: 10.1080/14796694.2026.2671256. Epub 2026 May 24. PubMed 42177753 ↗
  • Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31. PubMed 40450141 ↗
  • Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8. PubMed 38189180 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Dec 2024, 59 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 15, 2019
StartActual
Dec 30, 2019
Primary completionActual
Dec 2, 2024
CompletionEst.
Dec 2, 2026
Results first posted
Jan 22, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 5 sites removed
Show 7 added (2 Russia, 1 Canada, 1 France, 1 Germany, 1 Italy, 1 Japan)
  • McMaster Institute of Urology/St Joseph's Healthcare Hamilton · Hamilton, Canada
  • Hôpital Privé d'Antony · Antony, France
  • Universitaetsklinikum Tuebingen, Radiologische Universitätsklinik · Tübingen, Germany
  • Ospedale Policlinico San Martino, IRCCS · Genova, Italy
  • Kindai University Hospital · Sakai, Japan
  • National Medical Research Radiological Center of the Ministry of Health of the Russian Federation · Obninsk, Russia
  • Federal Budgetary Institution of Healthcare "Privolzhsky District Medical Center of the Federal · Nizhny Novgorod, Russia
Show 5 removed
  • Eastern Clinical Research Unit · Box Hill, Australia
  • Yarra Ranges Health · Lilydale, Australia
  • IRCCS Azienda Ospedaliera Universitaria Policlinico San Martino Urologia · Genova, Italy
  • Kindai University Hospital · Sayama, Japan
  • National Medical Research Radiological Centre of the MoH of the Russian Federation · Obninsk, Russia
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    7 sites added, 5 sites removed
    Show 7 added (2 Russia, 1 Canada, 1 France, 1 Germany, 1 Italy, 1 Japan)
    • McMaster Institute of Urology/St Joseph's Healthcare Hamilton · Hamilton, Canada
    • Hôpital Privé d'Antony · Antony, France
    • Universitaetsklinikum Tuebingen, Radiologische Universitätsklinik · Tübingen, Germany
    • Ospedale Policlinico San Martino, IRCCS · Genova, Italy
    • Kindai University Hospital · Sakai, Japan
    • National Medical Research Radiological Center of the Ministry of Health of the Russian Federation · Obninsk, Russia
    • Federal Budgetary Institution of Healthcare "Privolzhsky District Medical Center of the Federal · Nizhny Novgorod, Russia
    Show 5 removed
    • Eastern Clinical Research Unit · Box Hill, Australia
    • Yarra Ranges Health · Lilydale, Australia
    • IRCCS Azienda Ospedaliera Universitaria Policlinico San Martino Urologia · Genova, Italy
    • Kindai University Hospital · Sayama, Japan
    • National Medical Research Radiological Centre of the MoH of the Russian Federation · Obninsk, Russia
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04165317
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Dec 30, 2019
Primary completion
Dec 2, 2024
Completion
Dec 2, 2026 (estimated)
Results posted
Jan 22, 2026
Last update
Oct 15, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sasanlimab · BCG Vaccine

Start the discussion